Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos NV    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
180.5(c) 175.5(c) 177.85(c) 171.6(c) 170.9 Last
234 708 260 862 323 050 368 296 189 897 Volume
+0.33% -2.77% +1.34% -3.51% -0.41% Change
More quotes
Financials
Sales 2020 605 M 686 M 686 M
Net income 2020 -74,0 M -83,8 M -83,8 M
Net cash position 2020 1 596 M 1 808 M 1 808 M
P/E ratio 2020 -530x
Yield 2020 -
Sales 2021 645 M 731 M 731 M
Net income 2021 -142 M -161 M -161 M
Net cash position 2021 1 396 M 1 581 M 1 581 M
P/E ratio 2021 -101x
Yield 2021 -
Capitalization 11 198 M 12 668 M 12 683 M
EV / Sales 2020 15,9x
EV / Sales 2021 15,2x
Nbr of Employees 1 130
Free-Float 74,2%
More Financials
Company
Galapagos NV specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales break down by activity as follows: - discovery and development of drugs (98.8%); - other (1.2%). Net sales are distributed geographically as follows: Europe (5.8%) and North America (94.2%). 
More about the company
Surperformance© ratings of Galapagos NV
Trading Rating : Investor Rating :
More Ratings
Latest news on GALAPAGOS NV
06/08GILEAD SCIENCES : New Analyses of Phase 2 EQUATOR Clinical Program Support Durab..
AQ
06/05GALAPAGOS : New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Eff..
BU
06/05New analyses of phase 2 equator clinical program support durable ef..
GL
06/04GALAPAGOS : Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profi..
BU
06/04Filgotinib demonstrates durable efficacy and consistent safety profile..
GL
05/28Galapagos increases share capital through subscription right exercises
GL
05/28GALAPAGOS NV : Threshold crossings
CO
05/20Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals
RE
05/20GILEAD, GALAPAGOS : Filgotinib 200mg Achieved Primary Endpoints in Phase 2b/3 Tr..
DJ
05/20GALAPAGOS : Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3..
BU
05/20Gilead and galapagos announce positive topline results of phase 2b/3..
GL
05/11GALAPAGOS : Written questions
PU
05/07GALAPAGOS : Q1 Report 2020 pdf
PU
05/07On track for clinical read-outs and commercial readiness in 2020
GL
05/04GALAPAGOS NV : quaterly earnings release
More news
News in other languages on GALAPAGOS NV
06/08GILEAD SCIENCES : New Analyses of Phase 2 EQUATOR Clinical Program Support Durab..
06/08GALAPAGOS : données positives dans l'arthrite psoriasique
06/05GALAPAGOS : New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Eff..
06/05New analyses of phase 2 equator clinical program support durable ef..
06/04GALAPAGOS : Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profi..
More news
Stock Trading Strategies
GALAPAGOS - 03/20
A support level that should be taken advantage of
BUY
More Stock Trading Analysis
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 195,00 €
Last Close Price 171,60 €
Spread / Highest target 36,9%
Spread / Average Target 13,6%
Spread / Lowest Target -37,1%
EPS Revisions
Managers
NameTitle
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Operating & Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS NV-7.99%12 668
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344